Company: Forty Seven, Inc.
Symbol: FTSV
Description: They are a clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer.
Trade Date: 6/28
Shares: 6.7 million
Price Range: $14.00-$16.00
Underwriter(s): Morgan Stanley, Credit Suisse
Co-Manager(s): BTIG, Canaccord Genuity, Oppenheimer & Co.
Terms Added: 6-18-18
Business: They founded Forty Seven based on the insight that blocking CD47, a key signaling molecule that is overexpressed on cancer cells, renders tumors susceptible to macrophages. By harnessing macrophages, they believe that their lead product candidate, 5F9, dosed as a monotherapy or in combination with marketed cancer therapies, can transform the treatment of cancer. 5F9 has demonstrated promising activity in six Phase 1b/2 clinical trials in which they have treated over 190 relapsed or refractory cancer patients with solid or hematologic tumors. They hold worldwide rights to all of their product candidates.
Insider Buying: Certain of their existing stockholders or their affiliates, including entities affiliated with our directors, and certain other persons have indicated an interest in purchasing up to an aggregate of $30.0 million in shares of their common stock in this offering at the initial public offering price.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish